FLOW Trial: Renal Benefits of Semaglutide in T2DM Similar Regardless of Baseline CV Risk
Key Points Both chronic kidney disease (CKD) and cardiovascular disease (CVD) are prevalent in type 2 diabetes (T2DM), contributing to morbidity and mortality. The... Read more.
ARREST-AF: Aggressive Risk Factor Management After AF Ablation Reduces Arrythmia Recurrence at 12 Months
Key Points Observation data has suggested that improving cardiometabolic risk factors after AF ablation may reduce the recurrence of arrythmias. The ARREST-AF trial... Read more.
SUMMIT CMR: Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related HFpEF
Key Points Obesity-related heart failure with preserved ejection fraction (HFpEF) is associated with increased left ventricular (LV) concentric remodeling and paracardiac... Read more.
SCAN-MP Study: High Prevalence of Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals with Heart Failure
Key Points ATTR cardiac amyloidosis (ATTR-CA) is frequently diagnosed in older Black individuals with heart failure (HF), particularly in men over 75 years of age.... Read more.
A SUMMIT Analysis: Tirzepatide Reduces End Organ Damage in Patients with Obesity and HFpEF
Key Points SUMMIT, a randomized control trial of tirzepatide versus placebo in patients with HFpEF and obesity, found that tirzepatide significantly reduced the... Read more.
NUDGE-FLU Pool Analysis: Email Reminders Highlighting CV Benefits of Flu Shots Effective for Increasing Vaccine Uptake Post-MI
Key Points Three prior randomized trials including over two million adults in Denmark demonstrated that a variety of electronic message reminders, or “nudges”,... Read more.
ZODIAC: A Risk-based Decision Support System Did Not Significantly Improve Lipid-Lowering vs Usual Care
Key Points Maximizing lipid lowering therapy (LLTs) to optimize residual cardiovascular disease (CVD) risk after acute coronary syndrome (ACS) is usually a stepwise... Read more.
SUMMIT: Tirzepatide Decreased The Risk Of Worsening HF And CV Death in HFpEF + Obesity
Key Points SUMMIT was a multi-national trial that compared cardiovascular outcomes among patients with heart failure with preserved ejection fraction (HFpEF) and... Read more.
BPROAD: Intensive Blood Pressure Target Reduces MACE in Type 2 Diabetes
Key Points BPROAD was a randomized control trial in China that assigned nearly 13,000 participants with type 2 diabetes (T2DM) and hypertension (HTN) to either a... Read more.